If you have been diagnosed with breast cancer following use of Prempro, Premarin or Provera, you may be entitled to compensation.

You should act immediately to contact a lawyer experienced in matters involving defective pharmaceuticals.

We have represented thousands of people, including some of the largest and most important injury cases ever brought in the United States.

In the single largest damages case in the history of the world, our attorneys were selected by the Arizona Attorney General as the only Arizona law firm to represent the State against American tobacco companies. As a result, Arizona taxpayers will receive more than three billion dollars to cover the costs of treating tobacco-related illnesses, maintain educational programs to prevent young people from smoking, and fund other important State programs.

We have compiled the latest news on lawsuits filed against Wyeth for injuries caused by Prempro. All of the news articles on this page require Adobe Acrobat to view.

If you or a loved one has been injured by Prempro and you would like more information on litigation against the manufacturer, please contact us.

A jury has levied a $134.5 million judgment against the pharmaceutical maker Wyeth in a lawsuit filed by three Nevada women who contended that the company's hormone-replacement drugs had caused their breast cancer.

It was the largest award to date against Wyeth, of Madison, N.J., which faces more than 5,000 similar lawsuits against the country in state and federal courts.

A state jury in Philadelphia on Monday found Wyeth's hormone replacement therapy (HRT) Prempro was responsible for a woman's breast cancer and ordered the U.S. drugmaker to pay $1.5 million in compensatory damages, a court official said.

The jury found that Wyeth was negligent in failing to provide adequate warnings about the breast cancer risk associated with Prempro.

A case in which a married couple won a $1.5 million jury award after blaming Prempro, a hormone-replacement drug, for the woman's breast cancer ended yesterday with a a mistrial.

The lawyer for Jennie Nelson, of Dayton, Ohio, and a spokesman for drug maker Wyeth, the defendant, both said the grounds for the mistrial were sealed by the judge who declared it.

The same day a Philadelphia jury ruled that a hormone replacement drug at least partially caused a woman's breast cancer, a Reno woman who is dying of the disease reached an out-of-court settlement with the New Jersey-based drug maker.

Just two days before her trial was to begin, Carol McCreary and Wyeth Pharmaceuticals told Washoe District Judge Robert Perry on Wednesday they have resolved the case. Both sides agreed that the terms of the settlement will remain confidential.

A Philadephia jury found Wednesday that Wyeth's Prempro hormone-therapy drug was a significant cause of breast cancer in a 66-year-old woman and awarded $1.5 million in compensatory damages.

The verdict in state court, reached on the sixth day of jury deliberations, was Wyeth's first loss in litigation involving about 5,000 lawsuits claiming that Prempro and a related drug caused breast cancer and other diseases. Many of the suits were prompted by government studies showing a link between the drugs and increased risk for the diseases.

The Food and Drug Administration's Center for Drug Evaluation and Research has announced it will reassess the risks and benefits of Prempro, a hormone replacement therapy drug.

In a statement Tuesday, the FDA said that the Department of Health and Human Services will host public sessions on the issue in the fall. It said
that other combination estrogen/progestin products will be considered and that the findings may affect future clinical trials of hormone replacement therapy.

In a move that may affect millions of women, U.S. government scientists Tuesday stopped a major study of hormone replacement therapy on the risks and benefits of combined estrogen and progestin in healthy menopausal women, citing an increased risk of invasive breast cancer.

Researchers from the National Heart, Lung and Blood Institute of the National Institutes of Health also found increases in coronary heart disease, stroke and pulmonary embolism.

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has stopped early a major clinical trial of the risks and benefits of combined estrogen and progestin in healthy menopausal women due to an increased risk of invasive breast cancer.

The large multi-center trial, a component of the Women's Health Initiative (WHI), also found increases in coronary heart disease, stroke, and pulmonary embolism in study participants on estrogen plus progestin compared to women taking placebo pills. There were noteworthy benefits of estrogen plus progestin, including fewer cases of hip fractures and colon cancer, but on balance the harm was greater than the benefit.

The study, which was scheduled to run until 2005, was stopped after an average follow-up of 5.2 years.

O'Steen & Harrison, PLC presently is handling legal claims on behalf of those injured by Prempro.

If you or a loved one has been injured by Prempro and you would like more news about the Ortho Evra lawsuit, just call us toll-free at 1-800-883-8888 or complete this online contact form.